Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05696444 · ClinicalTrials.gov registry record · NA

Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)

A NA study of Prostate Cancer and Bladder Cancer, sponsored by Medtronic - MITG.

Active
Registry status
NA
Development phase
144
Enrollment target
6
Study locations

NCT05696444: Active NA study of Prostate Cancer and Bladder Cancer, sponsored by Medtronic - MITG.

NCT05696444 is a NA study of Prostate Cancer and Bladder Cancer that is active but no longer recruiting, run by Medtronic - MITG. The registered enrollment target is 144 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (76% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05696444, a NA study of Prostate Cancer and Bladder Cancer, is active but no longer recruiting, sponsored by Medtronic - MITG.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
144 participants
Enrollment target
6
Study locations

Study Summary

This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures.

Primary Outcome

The primary effectiveness endpoint is the surgical success rate, defined as the procedure not going into conversion. Conversion is defined as the switch from a robotic assisted approach using the Hugo system to a robotic assisted approach utilizing an FDA cleared robotic-assisted device, laparoscopic, or open surgery.

Conditions Studied

Prostate Cancer Bladder Cancer End Stage Renal Disease Kidney Cancer Interstitial Cystitis Kidney Injury Congenital Abnormalities Renal Tumor Pelvic Tumor

Interventions

  • DEVICE RAS Prostatectomy
  • DEVICE RAS Cystectomy
  • DEVICE RAS Nephrectomy

Study Locations (6)

California

  • City of Hope - Duarte

Illinois

  • University of Chiago - Chicago

New York

  • Mount Sinai - New York

North Carolina

  • Duke Medical Center - Durham

Ohio

  • Cleveland Clinic - Cleveland

Washington

  • Swedish Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2022-12-14
Est. Completion 2030-01-31
Phase NA
Medtronic - MITG

119 total trials

What the registry record for NCT05696444 still lists

NCT05696444 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (76% lower).

The record links to 9 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which RAS Prostatectomy is the first listed.

NCT05696444 lists 6 locations in 6 states (California, Illinois, New York).

Frequently Asked Questions

What is clinical trial NCT05696444 about?

NCT05696444 is a clinical study titled "Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)". This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures.

What is the current status of trial NCT05696444?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2022-12-14. Estimated completion is 2030-01-31.

What conditions does trial NCT05696444 study?

This clinical trial studies the following conditions: Prostate Cancer, Bladder Cancer, End Stage Renal Disease, Kidney Cancer, Interstitial Cystitis.

What interventions are being tested in trial NCT05696444?

The interventions under investigation include: RAS Prostatectomy (DEVICE), RAS Cystectomy (DEVICE), RAS Nephrectomy (DEVICE).

Who is sponsoring clinical trial NCT05696444?

This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05696444 being conducted?

This trial has 6 study locations across California, Illinois, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05696444's enrollment target sits among peer trials

144 275th of 735 higher than 460 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05696444, the US trial registry maintained by the National Library of Medicine. NCT05696444 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.